{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:17:26Z","timestamp":1772461046127,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier","isbn-type":[{"value":"9780128122655","type":"print"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/bs.vh.2017.03.002","type":"book-chapter","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T03:00:15Z","timestamp":1492657215000},"page":"249-271","source":"Crossref","is-referenced-by-count":14,"title":["Erythropoietin Promotes Glioblastoma via miR-451 Suppression"],"prefix":"10.1016","author":[{"given":"Begum","family":"Alural","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep O.","family":"Ayyildiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kemal U.","family":"Tufekci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sermin","family":"Genc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kursad","family":"Genc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/bs.vh.2017.03.002_bb0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pharmthera.2015.05.005","article-title":"Glioblastoma multiforme: Pathogenesis and treatment","volume":"152","author":"Alifieris","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/bs.vh.2017.03.002_bb0010","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fimmu.2014.00475","article-title":"EPO mediates neurotrophic, neuroprotective, anti-oxidant, and anti-apoptotic effects via downregulation of miR-451 and miR-885-5p in SH-SY5Y neuron-like cells","volume":"5","author":"Alural","year":"2014","journal-title":"Frontiers in Immunology"},{"issue":"12","key":"10.1016\/bs.vh.2017.03.002_bb0015","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1535-7163.1525.3.12","article-title":"Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin","volume":"3","author":"Belenkov","year":"2004","journal-title":"Molecular Cancer Therapeutics"},{"issue":"1","key":"10.1016\/bs.vh.2017.03.002_bb0020","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jamaoncol.2015.3940","article-title":"Consensus on the existence of functional erythropoietin receptors on cancer cells","volume":"2","author":"Bennett","year":"2016","journal-title":"JAMA Oncology"},{"key":"10.1016\/bs.vh.2017.03.002_bb0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1756-9966-30-20","article-title":"Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549)","volume":"30","author":"Bian","year":"2011","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"19","key":"10.1016\/bs.vh.2017.03.002_bb0030","doi-asserted-by":"crossref","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","article-title":"Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury","volume":"97","author":"Brines","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/bs.vh.2017.03.002_bb0035","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3892\/etm.2011.198","article-title":"High expression levels of erythropoietin and its receptor are not correlated with shorter survival in human glioblastoma","volume":"2","author":"Brunotte","year":"2011","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10.1016\/bs.vh.2017.03.002_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10143-016-0709-8","article-title":"Current and future strategies for treatment of glioma","volume":"40","author":"Bush","year":"2016","journal-title":"Neurosurgical Review"},{"issue":"1","key":"10.1016\/bs.vh.2017.03.002_bb0045","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/1947601909356352","article-title":"Erythropoietin receptor signaling through STAT3 is required for glioma stem cell maintenance","volume":"1","author":"Cao","year":"2010","journal-title":"Genes & Cancer"},{"issue":"Suppl. 1","key":"10.1016\/bs.vh.2017.03.002_bb0050","first-page":"25","article-title":"Carbamylated erythropoietin: A prospective drug candidate for neuroprotection","volume":"8","author":"Chen","year":"2015","journal-title":"Biochemistry Insights"},{"issue":"6","key":"10.1016\/bs.vh.2017.03.002_bb0055","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1517\/14728222.2013.780599","article-title":"Targeting erythropoietin for chronic neurodegenerative diseases","volume":"17","author":"Chong","year":"2013","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"2","key":"10.1016\/bs.vh.2017.03.002_bb0060","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2174\/1871527314666150116123610","article-title":"MicroRNAs in glioblastoma: Role in pathogenesis and opportunities for targeted therapies","volume":"14","author":"Costa","year":"2015","journal-title":"CNS & Neurological Disorders Drug Targets"},{"key":"10.1016\/bs.vh.2017.03.002_bb0065","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3389\/fimmu.2014.00563","article-title":"Erythropoietin and cancer: The unintended consequences of anemia correction","volume":"5","author":"Debeljak","year":"2014","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/bs.vh.2017.03.002_bb0070","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/sj.mp.4001907","article-title":"Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin","volume":"12","author":"Ehrenreich","year":"2007","journal-title":"Molecular Psychiatry"},{"issue":"2","key":"10.1016\/bs.vh.2017.03.002_bb0075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11060-013-1108-4","article-title":"The role of the CXCR4 cell surface chemokine receptor in glioma biology","volume":"113","author":"Ehtesham","year":"2013","journal-title":"Journal of Neuro-Oncology"},{"issue":"6","key":"10.1016\/bs.vh.2017.03.002_bb0080","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/08977194.2014.985787","article-title":"Ephs and Ephrins in malignant gliomas","volume":"32","author":"Ferluga","year":"2014","journal-title":"Growth Factors"},{"issue":"14","key":"10.1016\/bs.vh.2017.03.002_bb0085","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.4161\/cc.9.14.12248","article-title":"microRNA-451: A conditional switch controlling glioma cell proliferation and migration","volume":"9","author":"Godlewski","year":"2010","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/bs.vh.2017.03.002_bb0090","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/neuonc\/nou292","article-title":"Belonging to a network\u2014microRNAs, extracellular vesicles, and the glioblastoma microenvironment","volume":"17","author":"Godlewski","year":"2015","journal-title":"Neuro-Oncology"},{"issue":"5","key":"10.1016\/bs.vh.2017.03.002_bb0095","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.molcel.2010.02.018","article-title":"MicroRNA-451 regulates LKB1\/AMPK signaling and allows adaptation to metabolic stress in glioma cells","volume":"37","author":"Godlewski","year":"2010","journal-title":"Molecular Cell"},{"key":"10.1016\/bs.vh.2017.03.002_bb0100","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/1471-2164-13-357","article-title":"Selective extracellular vesicle-mediated export of an overlapping set of microRNAs from multiple cell types","volume":"13","author":"Guduric-Fuchs","year":"2012","journal-title":"BMC Genomics"},{"key":"10.1016\/bs.vh.2017.03.002_bb0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.05.001","article-title":"An overview of microRNAs","volume":"87","author":"Hammond","year":"2015","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"3","key":"10.1016\/bs.vh.2017.03.002_bb0110","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.ijrobp.2008.06.1923","article-title":"Erythropoietin augments survival of glioma cells after radiation and temozolomide","volume":"72","author":"Hassouna","year":"2008","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"5","key":"10.1016\/bs.vh.2017.03.002_bb0115","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3892\/ijo.2012.1592","article-title":"Glioblastoma cell line-derived spheres in serum-containing medium versus serum-free medium: A comparison of cancer stem cell properties","volume":"41","author":"Hong","year":"2012","journal-title":"International Journal of Oncology"},{"issue":"5","key":"10.1016\/bs.vh.2017.03.002_bb0120","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000356193","article-title":"Physiology and pharmacology of erythropoietin","volume":"40","author":"Jelkmann","year":"2013","journal-title":"Transfusion Medicine and Hemotherapy"},{"issue":"3","key":"10.1016\/bs.vh.2017.03.002_bb0125","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.clp.2015.04.004","article-title":"Erythropoietin and neonatal neuroprotection","volume":"42","author":"Juul","year":"2015","journal-title":"Clinics in Perinatology"},{"issue":"1","key":"10.1016\/bs.vh.2017.03.002_bb0130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1474-4422(15)00339-7","article-title":"Traumatic brain injury research highlights in 2015","volume":"15","author":"Kochanek","year":"2016","journal-title":"The Lancet. Neurology"},{"issue":"4","key":"10.1016\/bs.vh.2017.03.002_bb0135","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1134\/S0006297913040019","article-title":"Role of microRNAs in mechanisms of glioblastoma resistance to radio- and chemotherapy","volume":"78","author":"Koshkin","year":"2013","journal-title":"Biochemistry (Moscow)"},{"issue":"3","key":"10.1016\/bs.vh.2017.03.002_bb0140","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1179\/1743132813Y.0000000284","article-title":"Erythropoietin exerts cell protective effect by activating PI3K\/Akt and MAPK pathways in C6 cells","volume":"36","author":"Kwon","year":"2014","journal-title":"Neurological Research"},{"issue":"6","key":"10.1016\/bs.vh.2017.03.002_bb0145","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/bs.vh.2017.03.002_bb0150","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2741\/4408","article-title":"Regeneration in the nervous system with erythropoietin","volume":"21","author":"Maiese","year":"2016","journal-title":"Frontiers in Bioscience"},{"issue":"12","key":"10.1016\/bs.vh.2017.03.002_bb0155","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.4088\/JCP.13m08839","article-title":"Recombinant human erythropoietin to target cognitive dysfunction in bipolar disorder: A double-blind, randomized, placebo-controlled phase 2 trial","volume":"75","author":"Miskowiak","year":"2014","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1016\/bs.vh.2017.03.002_bb0160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2990.2006.00820.x","article-title":"De novo erythropoietin receptor (EPO-R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival","volume":"33","author":"Mittelbronn","year":"2007","journal-title":"Neuropathology and Applied Neurobiology"},{"issue":"2","key":"10.1016\/bs.vh.2017.03.002_bb0165","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3171\/jns.2007.106.2.338","article-title":"Survival and invasiveness of astrocytomas promoted by erythropoietin","volume":"106","author":"Mohyeldin","year":"2007","journal-title":"Journal of Neurosurgery"},{"key":"10.1016\/bs.vh.2017.03.002_bb0170","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.brainres.2010.08.074","article-title":"MiRNA-451 plays a role as tumor suppressor in human glioma cells","volume":"1359","author":"Nan","year":"2010","journal-title":"Brain Research"},{"issue":"1","key":"10.1016\/bs.vh.2017.03.002_bb0175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11060-010-0294-6","article-title":"Epo is involved in angiogenesis in human glioma","volume":"102","author":"Nico","year":"2011","journal-title":"Journal of Neuro-Oncology"},{"issue":"1","key":"10.1016\/bs.vh.2017.03.002_bb0180","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10014-010-0007-z","article-title":"Angiogenesis and invasion in glioma","volume":"28","author":"Onishi","year":"2011","journal-title":"Brain Tumor Pathology"},{"issue":"7","key":"10.1016\/bs.vh.2017.03.002_bb0185","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1158\/1535-7163.MCT-12-0802","article-title":"The potential role of miR-451 in cancer diagnosis, prognosis, and therapy","volume":"12","author":"Pan","year":"2013","journal-title":"Molecular Cancer Therapeutics"},{"issue":"1","key":"10.1016\/bs.vh.2017.03.002_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2015.03.015","article-title":"Mechanisms regulating glioma invasion","volume":"362","author":"Paw","year":"2015","journal-title":"Cancer Letters"},{"issue":"5","key":"10.1016\/bs.vh.2017.03.002_bb0195","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s13054-014-0526-9","article-title":"Erythropoietin and organ protection: Lessons from negative clinical trials","volume":"18","author":"Pearl","year":"2014","journal-title":"Critical Care"},{"issue":"4","key":"10.1016\/bs.vh.2017.03.002_bb0200","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.18632\/oncotarget.2937","article-title":"Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe","volume":"6","author":"Peres","year":"2015","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/bs.vh.2017.03.002_bb0205","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.yexcr.2011.06.011","article-title":"Targeting the erythropoietin receptor on glioma cells reduces tumour growth","volume":"317","author":"Peres","year":"2011","journal-title":"Experimental Cell Research"},{"issue":"5","key":"10.1016\/bs.vh.2017.03.002_bb0210","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ccell.2015.09.008","article-title":"Erythropoietin stimulates tumor growth via EphB4","volume":"28","author":"Pradeep","year":"2015","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/bs.vh.2017.03.002_bb0215","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.radonc.2007.05.003","article-title":"Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo","volume":"83","author":"Said","year":"2007","journal-title":"Radiotherapy and Oncology"},{"issue":"4","key":"10.1016\/bs.vh.2017.03.002_bb0220","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bpa.2010.10.005","article-title":"Erythropoietin as neuroprotective and neuroregenerative treatment strategy: Comprehensive overview of 12 years of preclinical and clinical research","volume":"24","author":"Sargin","year":"2010","journal-title":"Best Practice & Research. Clinical Anaesthesiology"},{"issue":"7","key":"10.1016\/bs.vh.2017.03.002_bb0225","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nature Methods"},{"issue":"9","key":"10.1016\/bs.vh.2017.03.002_bb0230","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s00066-003-1110-4","article-title":"Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation","volume":"179","author":"Stuben","year":"2003","journal-title":"Strahlentherapie und Onkologie"},{"issue":"1","key":"10.1016\/bs.vh.2017.03.002_bb0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00424-015-1740-2","article-title":"Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis","volume":"468","author":"Suzuki","year":"2016","journal-title":"Pfl\u00fcgers Archiv: European Journal of Physiology"},{"issue":"4","key":"10.1016\/bs.vh.2017.03.002_bb0240","first-page":"1105","article-title":"MicroRNA miR-451 downregulates the PI3K\/AKT pathway through CAB39 in human glioma","volume":"40","author":"Tian","year":"2012","journal-title":"International Journal of Oncology"},{"key":"10.1016\/bs.vh.2017.03.002_bb0245","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13054-015-0761-8","article-title":"Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: A randomized, prospective, placebo-controlled clinical trial","volume":"19","author":"Tsai","year":"2015","journal-title":"Critical Care"},{"issue":"1","key":"10.1016\/bs.vh.2017.03.002_bb0250","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/neuonc\/nov244","article-title":"Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia\/macrophages in the brain","volume":"18","author":"van der Vos","year":"2016","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/bs.vh.2017.03.002_bb0255","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/mp.2010.51","article-title":"Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia","volume":"16","author":"Wustenberg","year":"2011","journal-title":"Molecular Psychiatry"},{"issue":"3","key":"10.1016\/bs.vh.2017.03.002_bb0260","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00228-005-0896-7","article-title":"The pharmacokinetics of erythropoietin in the cerebrospinal fluid after intravenous administration of recombinant human erythropoietin","volume":"61","author":"Xenocostas","year":"2005","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1016\/bs.vh.2017.03.002_bb0265","first-page":"1193","article-title":"Glioblastoma multiforme cells: Expression of erythropoietin receptor and response to erythropoietin","volume":"31","author":"Yin","year":"2007","journal-title":"International Journal of Oncology"},{"issue":"1","key":"10.1016\/bs.vh.2017.03.002_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12033-014-9796-3","article-title":"MiR-451 suppresses cell proliferation and metastasis in A549 lung cancer cells","volume":"57","author":"Yin","year":"2015","journal-title":"Molecular Biotechnology"},{"issue":"19","key":"10.1016\/bs.vh.2017.03.002_bb0275","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.3748\/wjg.v21.i19.5867","article-title":"MiR-451 inhibits proliferation of esophageal carcinoma cell line EC9706 by targeting CDKN2D and MAP3K1","volume":"21","author":"Zang","year":"2015","journal-title":"World Journal of Gastroenterology"},{"issue":"5","key":"10.1016\/bs.vh.2017.03.002_bb0280","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.bcp.2008.06.007","article-title":"Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1\/P-glycoprotein expression in human cancer cells","volume":"76","author":"Zhu","year":"2008","journal-title":"Biochemical Pharmacology"}],"container-title":["Vitamins and Hormones","Erythropoietin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0083672917300237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0083672917300237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T17:54:46Z","timestamp":1658944486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0083672917300237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9780128122655"],"references-count":56,"URL":"https:\/\/doi.org\/10.1016\/bs.vh.2017.03.002","relation":{},"ISSN":["0083-6729"],"issn-type":[{"value":"0083-6729","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}